Sotorasib (non-small cell lung cancer (NSCLC); KRAS G12C mutation; ≥ 1 prior therapies)

Subject:

• Active Substance: Sotorasib
• Name: Lumykras^®
• Therapeutic area: Non-small cell lung cancer (NSCLC)
• Pharmaceutical company: Amgen Europe B.V.

Time table:

• Start: 15.02.2022
• Final decision by G-BA: 04.08.2022

Comparative therapy:

• Patients with PD-1/PD-L1 antibody monotherapy as first line therapy:
  • No additional benefit proved 
• Patients with a cytotoxic chemotherapy as first line therapy:
  • No additional benefit proved
• Patients with either a PD-1/PD-L1 antibody in combination with a platinum-based chemotherapy or a sequential therapy with a PD-1/PD-L1 antibody and a platinum-based chemotherapy as first line therapy:
  • No additional benefit proved